Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

Study Overview
=================
Brief Summary
-----------------
This study will assess the bioequivalence (BE) of Lesinurad/Allopurinol Fixed-Dose Combination (FDC) Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects

Detailed Description
-----------------
The study will assess the BE between lesinurad/allopurinol 200/300 FDC tablets and coadministered lesinurad and allopurinol tablets in the fed state.

Official Title
-----------------
A Phase 1, Randomized, Open-Label, Replicate, Crossover Study to Assess the Bioequivalence of Lesinurad/Allopurinol Fixed-Dose Combination Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: lesinurad/allopurinol 200/300 FDC tablet
* Drug: lesinurad 200 mg
* Drug: allopurinol 300 mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject has a body mass index ranging between 18 kg/m2 and 30 kg/m2. Screening serum urate level is ≤ 7.0 mg/dL. Exclusion Criteria: Asian subject who has a positive test for the HLA-B*5801 allele. History or suspicion of kidney stones. Estimated creatinine clearance, as determined at Screening, of < 90 mL/min calculated by the Cockcroft-Gault formula using ideal body weight. Undergone major surgery within 3 months prior to Screening. Donated blood or experienced significant blood loss (> 450 mL) within 12 weeks prior to Day 1or has given a plasma donation within 4 weeks prior to Day 1. Inadequate venous access or unsuitable veins for repeated venipuncture. Received any strong or moderate enzyme-inducing drug or product within 2 months prior to Screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sequence ABBA<br>Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) | Drug: lesinurad/allopurinol 200/300 FDC tablet<br> <br> Drug: lesinurad 200 mg<br> <br> Drug: allopurinol 300 mg<br> <br> |
| Experimental: Sequence BABA<br>Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) | Drug: lesinurad/allopurinol 200/300 FDC tablet<br> <br> Drug: lesinurad 200 mg<br> <br> Drug: allopurinol 300 mg<br> <br> |
| Experimental: Sequence ABAB<br>Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) | Drug: lesinurad/allopurinol 200/300 FDC tablet<br> <br> Drug: lesinurad 200 mg<br> <br> Drug: allopurinol 300 mg<br> <br> |
| Experimental: Sequence BAAB<br>Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) | Drug: lesinurad/allopurinol 200/300 FDC tablet<br> <br> Drug: lesinurad 200 mg<br> <br> Drug: allopurinol 300 mg<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics (PK) endpoints in terms of maximum observed concentration (Cmax) for lesinurad/allopurinol 200/300 FDC tablets relative to lesinurad and allopurinol coadministered monocomponent tablets | Cmax is the maximum observed concentration of a drug after administration | Days 1, 8, 15, and 22 | 
| PK endpoints in terms of time of occurrence of maximum observed concentration (tmax) for lesinurad/allopurinol 200/300 FDC tablets relative to lesinurad and allopurinol coadministered monocomponent tablets | Tmax is the time of occurrence of cmax | Days 1, 8, 15, and 22 | 
| PK endpoints in terms of area under plasma concentration time curve from zero to the last quantifiable sampling timepoint (AUC last) for lesinurad/allopurinol 200/300 FDC tablets relative to lesinurad and allopurinol coadministered monocomponent tablets | AUC last is a measure of total plasma concentration from time zero to the last measurable concentration | Days 1, 8, 15, and 22 | 
| PK endpoints in terms of area under the plasma concentration time curve from and from zero to infinity (AUC 0-∞) for lesinurad/allopurinol 200/300 FDC tablets relative to lesinurad and allopurinol coadministered monocomponent tablets | AUC 0-∞ is a measure of total concentration from time zero to infinity | Days 1, 8, 15, and 22 | 
| PK endpoints in terms of apparent terminal half-life (t1/2) for lesinurad/allopurinol 200/300 FDC tablets relative to lesinurad and allopurinol coadministered monocomponent tablets | t1/2 is a measure of apparent terminal half-life | Days 1, 8, 15, 22 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Adverse Events in terms of changes in laboratory parameters |  | 8 weeks | 
| Incidence of Adverse Events in terms of electrocardiogram parameters |  | 8 weeks | 
| Incidence of Adverse Events in terms of vital signs |  | 8 weeks |